Pfizer Alleges Micro Labs Infringing on Xeljanz Patents
Health your username March 12, 2021 On Thursday in the District of Delaware, Pfizer Inc. and its subsidiaries filed a complaint against Micro Labs Ltd. and its subsidiary, alleging infringement of its patents for drug Xeljanz. Pfizer holds the new drug application (NDA) for 10 mg tofacitinib citrate tablets, under the brand name Xeljanz, used to treat adults with ulcerative colitis, the complaint said. The patents-in-suit corresponding to Xeljanz are U.S. Patents Nos. RE41,783 and 6,965,027, which are set to expire Dec. 8, 2025, and March 25, 2023, respectively, according to the Food and Drug...